Сравнение
Glepaglutide vs. Octreotide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
нет данных
83150-76-9
Молекулярная масса
нет данных
1019.24 g/mol
Период полувыведения
нет данных
1.7 h
Последовательность
нет данных
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Механизм действия
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
5
из них на людях
1
4
Зафиксированные эффекты
2
3
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Glepaglutide and Octreotide?
- Glepaglutide is classified as "Исследования (прочее)", while Octreotide is classified as "Исследования (прочее)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Glepaglutide or Octreotide?
- The highest available evidence level is "РКИ на людях" for Glepaglutide and "РКИ на людях" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Glepaglutide and Octreotide in Germany and the United States?
- Германия: Glepaglutide — Не одобрено, Octreotide — Рецептурный. США: Glepaglutide — Не одобрено, Octreotide — Рецептурный. These are factual summaries with source and review date on the individual pages.